- PLN31.71m
- PLN26.47m
- PLN23.01m
- 92
- 29
- 20
- 41
Annual income statement for Genomed SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | PAS | PAS | PAS | PAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18.8 | 19.9 | 20.5 | 22.5 | 23 |
| Cost of Revenue | |||||
| Gross Profit | 6.61 | 7.78 | 7.81 | 9.6 | 10.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.3 | 18.6 | 20.1 | 21.2 | 21.8 |
| Operating Profit | 0.468 | 1.34 | 0.357 | 1.24 | 1.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.409 | 1.33 | 0.369 | 1.05 | 1.21 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.412 | 1.24 | 0.338 | 0.926 | 1.11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.412 | 1.24 | 0.338 | 0.926 | 1.11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.412 | 1.24 | 0.338 | 0.926 | 1.11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.312 | 0.937 | 0.256 | 0.701 | 0.839 |
| Dividends per Share |